What happens to value of information measures as the number of decision options increases?

Health Economics

Volumn 20, Issue 7, 2011, Pages 853-863

  Barton, Pelham ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cost effectiveness acceptability frontier; Decision making; Uncertainty; Value of information

Indexed keywords

ARTICLE; CANCER SCREENING; COST EFFECTIVENESS ACCEPTABILITY FRONTIER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; EXPECTED VALUE OF PERFECT INFORMATION; HUMAN; INFORMATION; NEOPLASM; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL ANALYSIS;

AGE FACTORS; BAYES THEOREM; CHOICE BEHAVIOR; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; HUMANS; INFORMATION DISSEMINATION; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS;

EID: 79953731754     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1651     Document Type: Article

References (8)

1. Barton GR, Briggs AH, Fenwick EAL. 2008. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfect information (EVPI). Value in Health 11: 886-897.
2. Barton P, Bryan S, Robinson S. 2004. Modelling in the economic evaluation of health care: selecting the appropriate approach. Journal of Health Services Research and Policy 9: 110-118. (Pubitemid 38568540)
3. Brennan A, Chick SE, Davies RM. 2006. A taxonomy of model structures for economic evaluation of health technologies. Health Economics 15: 1295-1310. (Pubitemid 44941606)
4. Claxton K. 1999. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18: 341-364. (Pubitemid 29242816)
5. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. 2005. Methods for the Economic Evaluation of Health Care Programmes (3rd edn). Oxford University Press: Oxford.
6. Fenwick E, Claxton K, Sculpher M. 2001. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 100: 779-787. (Pubitemid 34041389)
7. Karnon J, Czoski-Murray C, Smith KJ, Brand C. 2009. A hybrid cohort individual sampling natural history model of age-related macular degeneration: assessing the cost-effectiveness of screening using probabilistic calibration. Medical Decision Making 29: 304-316.
8. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. 1994. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 3: 309-319.